Benitec Biopharma Inc. cash flow to debt ratio of -2.78K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Benitec Biopharma Inc.'s free cash flow has decreased 20.55% from $-19.58M last year to $-23.61M, signaling decreasing performance

Benitec Biopharma Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Benitec Biopharma Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.00 today, signaling strengthened financials

Benitec Biopharma Inc. has a net cash position, so leverage is healthy.

Benitec Biopharma Inc.'s interest coverage ratio of 15.69 indicates that earnings with good margin can cover interest payments on company debt

Benitec Biopharma Inc. has insufficient data to evaluate this check.

Benitec Biopharma Inc.'s short-term assets of $98.52M exceed its short-term liabilities of $1.80M

Benitec Biopharma Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Benitec Biopharma Inc.'s return on equity of -34.82%, is lower than 15.00%, indicating bad performance

Benitec Biopharma Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Benitec Biopharma Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Benitec Biopharma Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Benitec Biopharma Inc. has negative free cash flow, indicating cash burn

Benitec Biopharma Inc.'s yearly earnings has decreased 74.32% since last year from $-21.75M to $-37.92M, signaling decreasing performance

Benitec Biopharma Inc.'s yearly revenue has decreased 100.00% since last year from $216.00K to $0.00, signaling decreasing performance

ROIC -29.28% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Benitec Biopharma Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Benitec Biopharma Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Benitec Biopharma Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Benitec Biopharma Inc. has insufficient data to evaluate this check.

Benitec Biopharma Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Benitec Biopharma Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Benitec Biopharma Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Benitec Biopharma Inc. has insufficient data to evaluate this check.

Benitec Biopharma Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Benitec Biopharma Inc. has a price-to-book ratio of 3.71x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Benitec Biopharma Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue